Detailed explanation of the domestic price and purchase information of Mobotinib (Mobosetinib)

Mobocertinib (Mobocertinib), as an innovative drug developed by Japan's Takeda Pharmaceutical Co., Ltd., is a third-generation tyrosine kinase inhibitor (TKI). It is designed to treat EGFR (epidermal growth factor receptor) exon 20 insertion mutations in patients with non-small cell lung cancer (NSCLC). Such mutations often show resistance to traditional EGFR-TKI drugs, and Mobotinib (Mobosetinib) can provide patients with a new and effective treatment option by irreversibly binding and inhibiting the tyrosine kinase activity of these mutants.

In clinical trials, Mobotinib (Mobosetinib) has demonstrated significant efficacy, especially in prolonging progression-free survival and improving objective response rates. In 2021, it received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with non-small cell lung cancer with EGFRexon 20 insertion mutations. The advent of this drug has brought new treatment hope to patients who have not responded to traditional treatment options and significantly improved their quality of life and prognosis.

In China, Mobotinib (Mobosetinib) is already on the market, but has not yet been included in the National Reimbursement Directory. This means the patient has to pay for it out of pocket. Despite this, its introduction still brings new treatment options to patients with non-small cell lung cancer with EGFRexon20 insertion mutations in China. Patients can obtain detailed information and purchasing channels aboutmobosetinibby consulting the oncology department or pharmacy of their local hospital.

As for the price, sincemobosetinib (mobosetinib) has not been included in the medical insurance, patients need to bear the cost of the drug themselves. In China, the selling price of Mobotinib (Mobosetinib) is relatively high, with monthly treatment costs ranging from RMB 7,000 to RMB 8,000. This is a significant financial burden for most patients. Therefore, before purchasing, patients are advised to fully understand the price of the drug and make decisions based on their own financial affordability.